The Healing Power of Botanical Therapeutics®


National Investment Banking Association, Inc. (NIBA) Conference in New York City, June 6th-8th, 2012

Press Release: Herborium Group, Inc. — June 5, 2012 8:45 AM EDT

FORT LEE, N.J., June 5, 2012 /PRNewswire/ -- Herborium Group, Inc. (HBRM) is pleased to announce that Management will present the Company's unique Botanical Therapeutics® opportunity and its operating success at the National Investment Banking Association, Inc. (NIBA) meeting in New York City, June 6th-8th, 2012. NIBA is the only national not-for-profit trade association of regional and independent brokerages, investment banking firms, and related capital market service providers. NIBA is a premier forum for quality small capital companies seeking access and exposure to underwriters and broker/dealers in connection with their capital formation, and other financial objectives. Presentations are by invitation and Herborium presents at the general session on Thursday, as well as being scheduled for a number of the One on One Meetings on Friday.

"We are extremely excited to have the privilege to present at the NIBA forum and to share Herborium's Botanical Therapeutics® opportunity as well as the company's operating success with a number of potential financial and business partners. This event provides both a validation of the Company's achievements to date and a great opportunity for developing valuable investment and growth partnerships for the future," noted Dr. Agnes Olszewski, CEO of Herborium.

Since its inception, NIBA member firms have successfully completed some 1000+ equity offerings totaling approximately $10 billion in new capital for America's finest emerging growth companies. The member firms of NIBA represent over 8800 registered representatives and with an estimated $78 billion assets under management.

About Herborium Group, Inc.

Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals.  The Company uses clinical validation to establish and maintain a differential advantage. The company sales its products in the US and Europe. For more information, please visit and

One of our most important responsibilities is to communicate with shareholders in an open and direct manner.  Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends."  We cannot promise future returns.  Our statements reflect our best judgment at the time, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events.  The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.

For more information please inquire:


Information provided on about medical conditions, symptoms, and related products is not intended to be a substitute for professional medical advice. Visitors to this site should not use this information to diagnose or treat a health problem, symptom, concern or disease without consulting with their individual qualified healthcare provider. Statements contained on this website have not been evaluated by the FDA. Herborium products are not intended to diagnose, heal, cure or prevent disease.